Bandingkan kaedah
Semak kaedah pilihan anda secara bersebelahan; baris yang berbeza akan diserlahkan.
| Skor Child-Pugh untuk Sirosis Hati× | Indeks Gejala Utama Gastroparesis× | |
|---|---|---|
| Bidang | Gastroenterologi | Gastroenterologi |
| Keluarga | Process / pipeline | Process / pipeline |
| Tahun asal≠ | 1964 (Child-Turcotte), 1973 (Pugh modification) | 2003 |
| Pengasas≠ | Child, C. G., Turcotte, J. G., and Pugh, R. N. | Revicki, D. A., Rentz, A. M., Dubois, D., et al. |
| Jenis≠ | Clinician-rated | Self-report |
| Sumber perintis≠ | Child, C. G., & Turcotte, J. G. (1964). Surgery and portal hypertension. In C. G. Child (Ed.), The liver and portal hypertension (pp. 50–64). Saunders. link ↗ | Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150. link ↗ |
| Alias≠ | Child-Turcotte-Pugh Score, CTP Score | GCSI |
| Berkaitan | 4 | 4 |
| Ringkasan≠ | The Child-Pugh Score (originally Child-Turcotte, modified by Pugh in 1973) is a clinical scoring system that stratifies the severity of liver cirrhosis and predicts surgical mortality and prognosis. The score integrates five readily available clinical and laboratory parameters: bilirubin, albumin, prothrombin time (INR), ascites, and hepatic encephalopathy. With a total range of 5–15 points, the Child-Pugh Score is stratified into Class A (mild, 5–6 points), Class B (moderate, 7–9 points), and Class C (severe, 10–15 points), each with distinct mortality predictions. | The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response. |
| ScholarGateSet data ↗ |
|
|